July 17, 2026 a 09:00 am

REGN: Analysts Ratings - Regeneron Pharmaceuticals, Inc.

Historical Stock Grades

As of July 2026, Regeneron Pharmaceuticals, Inc. has seen a stable stance from analysts with no sell recommendations. The majority of analysts recommend buying or strongly buying the stock, suggesting confidence in its future performance.

Recommendation	Count	Score
Strong Buy	5
Buy	16
Hold	8
Sell	0
Strong Sell	0

Sentiment Development

Over recent months, there has been notable stability in the sentiment surrounding Regeneron Pharmaceuticals, Inc. The total number of ratings has remained relatively steady, with slight fluctuations in individual categories.

• The number of 'Buy' recommendations has slightly decreased from a peak in March 2026 but remains a dominant sentiment.
• 'Hold' ratings have shown minor increases, indicating a cautious optimism amongst some analysts.
• No 'Sell' or 'Strong Sell' ratings highlight continued confidence in the company's prospects.

Percentage Trends

Analyzing the distribution of recommendations, it is clear that positive sentiment continues to dominate, though with subtle shifts towards cautiousness.

• As of July 2026, 'Strong Buy' recommendations represent approximately 19% of total ratings, consistently maintaining a supportive backing.
• 'Buy' recommendations account for 61%, solidifying the perspective of optimism among analysts.
• The 'Hold' category, making up 30% of recommendations, has seen slight growth, reflecting a moderate approach by some market watchers.
• Overall, while confidence prevails, a careful assessment is being observed as analysts balance expectations with market realities.

Latest Analyst Recommendations

Recent analyst activity showcases the maintenance of current ratings with occasional upgrades, reflecting both steady confidence and occasional boosts in stock confidence.

Date	New Recommendation	Last Recommendation	Publisher
2026-07-09	Overweight	Overweight	Piper Sandler
2026-07-08	Equal Weight	Equal Weight	Morgan Stanley
2026-07-07	Buy	Buy	Truist Securities
2026-07-07	Buy	Hold	Benchmark
2026-07-07	Sector Perform	Sector Perform	RBC Capital

Analyst Recommendations with Change of Opinion

There have been a few notable changes in analyst opinions, hinting at shifting perspectives as markets adjust expectations.

Date	New Recommendation	Last Recommendation	Publisher
2026-07-07	Buy	Hold	Benchmark
2026-05-18	Neutral	Buy	Citigroup
2026-05-18	Market Perform	Outperform	Leerink Partners
2026-01-07	Buy	Underperform	B of A Securities
2025-12-03	Equal Weight	Overweight	Morgan Stanley

Interpretation

The steady sentiment towards Regeneron Pharmaceuticals, Inc. suggests a generally positive outlook, reinforced by the absence of sell ratings. However, slight increases in 'Hold' recommendations might indicate an undercurrent of caution or reassessment due to broader market factors. Analysts appear to maintain a balanced view, with confidence in the company's fundamentals, though mindful of market volatilities.

Conclusion

Overall, Regeneron Pharmaceuticals, Inc. remains perceived as a favorable investment in the analyst community. The dominance of 'Buy' ratings alongside strategic upgrades suggests continuing confidence, though some analysts show tempered enthusiasm with 'Hold' recommendations. The firm's innovative pipeline and strategic partnerships bolster its market presence. Investors should weigh the positive sentiment with emerging cautious tendencies reflected in recent analyses. The balance of opportunity and risk appears to remain relatively stable, supporting an outlook of guarded optimism in the near term.